U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07107204) titled 'A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies' on July 30.
Brief Summary: The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years .
Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.
Study Start Date: Aug., 20...